Unraveling Myeloid Cell Diversity in Cancer

Tumors growing in metabolically-challenged environments are particularly reliant on cancer cells and immune cell metabolic cross-talk to satisfy their high metabolic needs. However, the intricacies of this metabolic interplay and the consequences on immune cell subsets diversity and function remain largely unexplored. We interrogated the heterogeneity of the tumor microenvironment using multi-omics analyses in preclinical brain and liver cancer mouse models and patient datasets and identified metabolically-rewired tumor-associated macrophage (TAMs), myeloid cells and regulatory T cell subpopulations fueling cancer progression and resistance to standard of care and immunotherapies. Our work reveals the dynamic evolution of specific immune cell compartment and how they support disease relapse, with potential for exploiting these vulnerabilities therapeutically.